Clinical Trial Update: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether escitalopram prevents pegylated interferon–associated depression in hepatitis C patients; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Major Depressive Disorder

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Depression | Phase 3 | Status: COMPLETED | Results posted: 2013-03-21